ERYTECH Pharma (NASDAQ: ERYP) Upgraded by Zacks Investment Research From a “holding” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. Brokerage currently has a target price of $ 2.50 per share. Zacks Investment ResearchThe company’s price target will indicate a potential upside of 7.30% from the company’s previous closure.
According to Zacks, “Erytech Pharma SA operates as a bio-pharma company. It discovers and develops treatments for rare forms of cancer and orphan diseases. Erytech Pharma SA is based in France. “
Several other stock analysts also commented on ERYP. Jefferies Financial Group downgraded ERYTECH Pharma shares from a “buy” rating to a “hold” rating in a research report on Tuesday, November 2nd. JMP Securities downgraded ERYTECH Pharma shares from a “better performance” rating to a “market performance” rating in a research report on Monday, October 25th. Finally, Cowen downgraded ERYTECH Pharma shares from a “better performance” rating to a “market performance” rating in a research report on Monday, October 25th.
Shares of NASDAQ: ERYP Traded up $ 0.13 during midday trading on Tuesday, reaching $ 2.33. 106,872 shares of the company were exchanged, compared to an average volume of 340,291. The company’s fifty-day moving average is $ 2.95. ERYTECH Pharma has a low for the year of $ 2.09 and a year high of $ 13.00.
An institutional investor recently raised his position in the stock of ERYTECH Pharma. BVF Inc. IL increased its position in ERYTECH Pharma SA (NASDAQ: ERYP) by 110.3% during the second quarter, according to the company’s recent exposure with the Securities Authority. The firm held 1,314,656 shares of the company after acquiring an additional 689,656 shares during the quarter. BVF Inc. IL held approximately 4.98% of ERYTECH Pharma worth $ 6,376,000 at the end of the most recent reporting period. Institutional investors hold 6.97% of the company’s shares.
Company profile of ERYTECH Pharma
ERYTech Pharma SA is a bio-pharma company that develops medical products. The firm conducts research and development of innovative drugs based on red blood cells for cancer and orphan diseases. The company was founded by Pierre Olivier Guino and Ian Godparin on November 22, 2004 and is headquartered in Lyon, France.
See also: Technical Analysis
For more information on research proposals from Zack Investment Research, visit Zacks.com
This instant news alert was created using narrative scientific technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected]
Is it worth investing $ 1,000 in ERYTECH Pharma right now?
Before you consider ERYTECH Pharma, you will want to hear it.
MarketBeat tracks the top Wall Street analysts and the best performance and stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that leading analysts are quietly whispering to their clients to buy now before the broad market takes over … and ERYTECH Pharma was not on the list.
While ERYTECH Pharma currently has a “Hold” rating among analysts, high-ranking analysts believe these five stocks are better buys.
Watch the 5 stocks here